Commentary: The hazards of survival comparisons

Oncologist

Volumn 12, Issue 5, 2007, Pages 510-511

  Berry, Donald ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; DRUG EFFICACY; HAZARD RATIO; HEALTH INSURANCE; HUMAN; NOTE; PRIORITY JOURNAL;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 35548991362     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-5-510     Document Type: Note

References (4)

1. Lewis JP. An interpretation of the EBCTCG data. The Oncologist 2007; 12:505-509.
2. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-2746.
3. Berry DA. Statistical innovations in cancer research. In: Holland J, Frei T, eds. Cancer Medicine, Sixth Edition. London: BC Decker, 2003:465-478. [See also Seventh Edition, pp 411-425.]
4. Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-1667.